Log in

Relevant bibliographies by topics / Immuno suppressive therapy / Journal articles

To see the other types of publications on this topic, follow the link: Immuno suppressive therapy.

Journal articles on the topic 'Immuno suppressive therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immuno suppressive therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kodiyerithodi, Insaf, Shamsudeen Moideen, Benil Hafeeq, Jyothish Chalil Gopinathan, and Bhagyanath T. "Disseminated strongyloidiasis in patients on immuno-suppressive therapy." International Journal of Research in Medical Sciences 12, no. 4 (2024): 1293–96. http://dx.doi.org/10.18203/2320-6012.ijrms20240860.

Full text

Abstract:

Strongyloidiasis is a disease that causes significant morbidity and rarely mortality in immunocompromised patients. We report two cases of disseminated strongyloidiasis infection while on steroids. The first patient was a known diabetic, hypertensive, and coronary artery disease who began on steroids with hemodialysis for biopsy-proven rapidly progressive glomerulo nephritis (RPGN). He presented to the emergency department (ED) with fever, loose stools, worsening dyspnea on exertion, cough, conjunctival congestion, and bilateral lower limb pain of 1-week duration while on hemodialysis (HD). He

APA, Harvard, Vancouver, ISO, and other styles

2

Wicher, Krzysztof B., Moritz Haneklaus, Martha Lopez-Yrigoyen, et al. "Abstract LB040: MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner." Cancer Research 84, no. 7_Supplement (2024): LB040. http://dx.doi.org/10.1158/1538-7445.am2024-lb040.

Full text

Abstract:

Abstract Macrophages populate most solid tumors in large numbers and limit effective anti-tumoral immune responses. The leukocyte immunoglobulin-like receptors (LILR) such as e.g. LILRB1, LILRB2, and others are expressed on tumor associated macrophages. Despite sharing multiple ligands such as major histocompatibility complex class I G (HLA-G), these receptors regulate different macrophage functions such as phagocytosis or cytokine release. To date, therapeutic approaches to targeting LILRs have concentrated on blocking receptor-ligand interactions to relieve ligand-mediated immune suppression

APA, Harvard, Vancouver, ISO, and other styles

3

Tolaymat, Naser, and Clare Lenhart. "Vaccination Practice for Pediatric Inflammatory Disease Patients Receiving Immuno-suppressive Therapy." American Journal of Gastroenterology 108 (October 2013): S622—S623. http://dx.doi.org/10.14309/00000434-201310001-02051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dahal, Tshetiz, and Subarna Rizal. "INNATE IMMUNE CELLSIN IMMUNE TOLERANCE AFTER LIVER TRANSPLANTATION." International Journal of Advanced Research 10, no. 04 (2022): 506–15. http://dx.doi.org/10.21474/ijar01/14575.

Full text

Abstract:

Currently, liver transplantation is the most effective treatment for end-stage liver disease. Immuno-suppressive agents are required to be taken after the operations, which have significantly reduced rejection rates and improved the short-term (<1 year) survival rates. However, post-transplant complications related to the immuno-suppressive therapy have led to the development of new protocols aimed at protecting renal function and preventing de novo cancer and dysmetabolic syndrome. Donor specific immune tolerance, which means the mature immune systems of recipients will not attack the graf

APA, Harvard, Vancouver, ISO, and other styles

5

Ding, Peikun, Xiaoxiang Huang, Quanzhou Peng, et al. "Abstract 1597: Immune suppression of the lymph node microenvironment causes oligoprogression of metastatic cancer after neoadjuvant immuno-chemotherapy." Cancer Research 85, no. 8_Supplement_1 (2025): 1597. https://doi.org/10.1158/1538-7445.am2025-1597.

Full text

Abstract:

Abstract Oligometastatic disease is recognized as an intermediate state between localised and systemically metastasised disease. The diagnosis, treatment and prognosis of oligometastatic disease is currently based mainly on imaging examination. Previous clinical studies indicated that standard systemic therapy followed by radical local therapy was beneficial for survival in tumor patients with oligometastatic disease. However, different clinical outcomes (such as oligopersistant and oligoprogression) were found in synchronous and/or metachronous oligometastatic disease after the same systemic

APA, Harvard, Vancouver, ISO, and other styles

6

Singh, Alok, Priyambada Kumari, Shanker K. Singh, et al. "Pre- and post-therapy circulating immuno-stimulatory and immuno-suppressive cytokines in dogs with juvenile-onset generalized demodecosis." Veterinary Parasitology 275 (November 2019): 108954. http://dx.doi.org/10.1016/j.vetpar.2019.108954.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

DʼALESSANDRO, ANTHONY M., JOHN D. PIRSCH, ROBERT J. STRATTA, et al. "OKT3 SALVAGE THERAPY IN A QUADRUPLE IMMUNO SUPPRESSIVE PROTOCOL IN CADAVERIC RENAL TRANSPLANTATION." Transplantation 47, no. 2 (1989): 297–99. http://dx.doi.org/10.1097/00007890-198902000-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Park, Seong Jin, Seho Kweon, Moyo Knowledge Mudhibadhi, Ha Rin Kim, and Youngro Byun. "Abstract 5091: Potentiating immunogenicity of PD1 blockage with metronomic Oral CAPOX for local and liver metastasized colorectal cancer." Cancer Research 83, no. 7_Supplement (2023): 5091. http://dx.doi.org/10.1158/1538-7445.am2023-5091.

Full text

Abstract:

Abstract Since the appearance of oxaliplatin, FOLFOX therapy is positioned as the standard of care for colorectal cancer (CRC). And after the advent of capecitabine, an oral prodrug of 5-FU, both FOLFOX and CAPOX remain the first-line treatment for local and advanced CRC. Even though oral 5-FU prodrug has approved more than two decades ago, orally available oxaliplatin has not been developed yet. Oral chemotherapy has garnered attention in the era of cancer immunotherapy because oral form of the therapy makes metronomic therapy feasible. In this regard, we invented orally absorbable oxaliplati

APA, Harvard, Vancouver, ISO, and other styles

9

Venkateshappa, Chandregowda, Kishore Narayanan, Rashmi Nair, et al. "Abstract 4432: A highly differentiated A2AR inhibitor for potential use in cancer therapy." Cancer Research 83, no. 7_Supplement (2023): 4432. http://dx.doi.org/10.1158/1538-7445.am2023-4432.

Full text

Abstract:

Abstract As a potent immunosuppressor adenosine is essential for maintaining tissue homeostasis and preventing an overzealous immune response during inflammation and infection. However, adenosine generated within the tumor microenvironment by the action of ectonucleotides hinders the immune reaction towards cancer cells by signaling through adenosine receptors such as high affinity A2AR expressed on immune cells. Tumors evade the immune response by usurping pathways that negatively regulate normal immune responses. Resistance to inhibition of immune checkpoint targets arises because of an upre

APA, Harvard, Vancouver, ISO, and other styles

10

Galassi, Claudia, Martina Musella, Nicoletta Manduca, Ester Maccafeo, and Antonella Sistigu. "The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure." Cells 10, no. 9 (2021): 2361. http://dx.doi.org/10.3390/cells10092361.

Full text

Abstract:

Cancer stem cells (CSCs) are broadly considered immature, multipotent, tumorigenic cells within the tumor mass, endowed with the ability to self-renew and escape immune control. All these features contribute to place CSCs at the pinnacle of tumor aggressiveness and (immune) therapy resistance. The immune privileged status of CSCs is induced and preserved by various mechanisms that directly affect them (e.g., the downregulation of the major histocompatibility complex class I) and indirectly are induced in the host immune cells (e.g., activation of immune suppressive cells). Therefore, deeper in

APA, Harvard, Vancouver, ISO, and other styles

11

Rahmy, Sharif, and Xin Lu. "Histone deacetylase inhibition can revert induced resistance to immune checkpoint blockade in a mouse model of prostate cancer." Journal of Immunology 206, no. 1_Supplement (2021): 67.14. http://dx.doi.org/10.4049/jimmunol.206.supp.67.14.

Full text

Abstract:

Abstract Castration resistant prostate cancer (CRPC) is one of the leading causes of death in men in the United States, with a 5-year survival rate of 28%. Immune checkpoint blockade (PD-1 & CTLA4 inhibition, ICB) is a novel therapeutic strategy based on restoring the tumoricidal activity of cytotoxic T-lymphocytes. ICB therapy has produced spectacular results in the treatment of melanoma but shows almost no effect in CRPC. We have developed a model system of advanced prostate cancer (Pten−/−/Tp53−/−/Smad4−/−) consisting of a parental (ICB sensitive) cell line and an ICB resistant subline

APA, Harvard, Vancouver, ISO, and other styles

12

Wong, Andrew, Patrick Fadden, Cara Clouse, et al. "Abstract 4156: Site specific tumor response to combination chemotherapy and immune checkpoint inhibitor in the syngeneic Pan02 pancreatic ductal adenocarcinoma model." Cancer Research 83, no. 7_Supplement (2023): 4156. http://dx.doi.org/10.1158/1538-7445.am2023-4156.

Full text

Abstract:

Abstract Syngeneic tumor models provide a platform to assess novel immune-oncology therapeutics in fully immuno-competent mice. A subcutaneous flank tumor implant provides a convenient and accessible location to monitor the tumor growth and response to therapy. However, the tumor microenvironment, and therefore, the responsiveness to immuno-oncology therapies, is greatly impacted by the location in which the tumor develops (Ho 2021, Oliver 2018). Given the potential of different immuno-suppressive features driven by the specific tumor location, we wanted to compare the tumor infiltrating leuko

APA, Harvard, Vancouver, ISO, and other styles

13

Lea, Spencer, Chao-Hsien Chen, Jun Wei, Ivana William, and Michael Curran. "291 High Potency STING Agonists Induce Adaptive Immunity-Dependent Curative Responses in an Immune Checkpoint Blockade-Refractory Glioblastoma Model." Journal of Clinical and Translational Science 7, s1 (2023): 87–88. http://dx.doi.org/10.1017/cts.2023.347.

Full text

Abstract:

OBJECTIVES/GOALS: Glioblastoma (GBM) is the most common and aggressive adult primary brain malignancy. Clinically, GBM is refractory to T cell immune checkpoint blockade (ICB), in part due to its dense immune suppressive myeloid stroma. Here we show that myeloid-targeting STING agonists can repolarize the GBM microenvironment to cure ICB-refractory GBM models. METHODS/STUDY POPULATION: Using the synthetic cyclic di-nucleotide STING agonist IACS-8803 (8803) we treated orthotopic ICB-refractory QPP8 orthotopic murine GBM tumors intratumorally. We then analyzed survival and performed high paramet

APA, Harvard, Vancouver, ISO, and other styles

14

Mayer, Lena Sophie, Robert J. Orlowski, Josephine Giles, et al. "Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade." Journal of Immunology 204, no. 1_Supplement (2020): 165.42. http://dx.doi.org/10.4049/jimmunol.204.supp.165.42.

Full text

Abstract:

Abstract Overcoming acquired adaptive immune resistance to anti-PD-1 therapy is imperative for enhancing the efficacy of immune checkpoint blockade (ICB) in solid tumors. Regulatory T cells (Tregs) play a prominent role in the suppressive tumor microenvironment (TME) and are major contributors to adaptive immune resistance. Tregs limit CD8+ T cell reinvigoration and are a promising target for combination therapy. While the clinical efficacy of anti-CTLA4 may be partially explained by restriction of Tregs, its co-administration with anti-PD1 causes significant toxicity. Thus, safer approaches t

APA, Harvard, Vancouver, ISO, and other styles

15

Muralinath, E., H.S. Singh, Digamber D. Vijay, et al. "Exploring Therapeutic Approaches: Drugs Targeting Lung Fibrosis." Journal of Advances in Experimental Therapeutics and Neurotherapeutics 2, no. 1 (2024): 14–16. https://doi.org/10.5281/zenodo.10792420.

Full text

Abstract:

<em>Lung FIBROSIS. A condition  manifested by the progressive scarring of lung tissue and pses a significant health challenges worldwide. Pirfenidone is an anti-fibrotic drug and it is an FDA_ approved drug that performs by stopping the production of transforming growth factor_ beta (TGF_ beta ), a key player particularly in FIBROSIS. Another anti fibrotic drug such as nintedanonib targets multiple pathways participated in FIBROSIS, along with TGF_ beta pathway. Corticosteroids namely prednisone with an immune_ suppressing effect that can be used in decreasing inflammation linked to lung

APA, Harvard, Vancouver, ISO, and other styles

16

Prajapati, Kushal, Cynthia Perez, Brianna Burke, Lourdes Plaza-Rojas та Jose Alejandro Guevara-Patino. "NKG2D receptor activation makes CD8+ T cells resistant to the suppressive effects of TGF-β". Journal of Immunology 196, № 1_Supplement (2016): 142.8. http://dx.doi.org/10.4049/jimmunol.196.supp.142.8.

Full text

Abstract:

Abstract Natural killer group 2, member D (NKG2D) is a stimulatory receptor majorly present on the surface of natural killer and CD8+ T cells. We and others have shown that NKG2D receptor enhances the function, persistence and proliferation of CD8+ T cells. On the other hand, a major hurdle in the field of cancer vaccine and adoptive T cell transfer therapy (ACT) is diminished effectiveness and persistence of CD8+ T cells due to immuno-suppressive factors. TGF-β is a highly prevalent immuno-suppressive factor that negatively regulates the function and persistence of CD8+ T cells. We hypothesiz

APA, Harvard, Vancouver, ISO, and other styles

17

Prajapati, Kushal, та Jose Guevara-Patino. "Studying the antagonistic relationship between NKG2D and TGF-β in CD8+ T cells (IRM14P.449)". Journal of Immunology 194, № 1_Supplement (2015): 198.9. http://dx.doi.org/10.4049/jimmunol.194.supp.198.9.

Full text

Abstract:

Abstract One of the major hurdles in cancer vaccine and adoptive T cell transfer therapy (ACT) development is diminished effectiveness and persistence of T lymphocytes due to immuno-suppressive factors. TGF-β is highly prevalent immuno-suppressive factor secreted by tumor which negatively regulates persistence and functionality of CD8+ T cells. Natural killer group 2, member D (NKG2D) is a stimulatory receptor majorly expressed on the surface of NK and CD8+ T cells. Others including our lab have shown that NKG2D activation on CD8+ T cells enhances their function, proliferation and persistence.

APA, Harvard, Vancouver, ISO, and other styles

18

Rohlff, Christian, Solmaz Sahebjam, Alain Mita, et al. "Abstract 1975: Potential novel Immuno-oncology mechanism revealed during translational phase I Immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient." Cancer Research 82, no. 12_Supplement (2022): 1975. http://dx.doi.org/10.1158/1538-7445.am2022-1975.

Full text

Abstract:

Abstract CD205 is a type I transmembrane glycoprotein, with unique characteristics that make it an ideal target for Antibody Drug Conjugate (ADC) therapy. Here we report on a potential novel immuno-oncology mechanism revealed during the Translational Phase I (NCT04064359) immuno-blood profiling of a chemo-refractory patient treated with OBT076, an experimental CD205-directed ADC. A chemo-refractory advanced gastric cancer patient with 60% CD205 expression in the primary tumor via IHC and having previously undergone 2 lines of chemotherapy treatment (Docetaxel/cisplatin/5FU and Ramucirumab/Pacl

APA, Harvard, Vancouver, ISO, and other styles

19

Boregowda, Siddaraju V., Cori N. Booker, Jacqueline Strivelli, and Donald G. Phinney. "Mesenchymal Stem/Stromal Cells (MSCs) from Mouse Pelvic vs. Long Bones Exhibit Disparate Critical Quality Attributes: Implications for Translational Studies." Cells 14, no. 4 (2025): 274. https://doi.org/10.3390/cells14040274.

Full text

Abstract:

Mesenchymal stem/stromal cells (MSCs) have been exploited as an experimental cell therapy in a broad array of clinical applications but have underperformed based on results from pre-clinical studies due to gaps in translating pre-clinical findings to human patients. Herein, we isolated mouse MSCs from pelvic bone marrow (BMP), a preferred source for human MSCs, and compared their growth, differentiation, and immuno-modulatory activity to those derived from long bone marrow (BML), the traditional source of mouse MSCs. We report that BMP-MSCs exhibit significantly enhanced growth kinetics in 5%

APA, Harvard, Vancouver, ISO, and other styles

20

Donlon, Noel E., Maria Davern, Andrew Sheppard, et al. "The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling." Cancers 13, no. 16 (2021): 4005. http://dx.doi.org/10.3390/cancers13164005.

Full text

Abstract:

Response rates to the current gold standards of care for treating oesophageal adenocarcinoma (OAC) remain modest with 15–25% of patients achieving meaningful pathological responses, highlighting the need for novel therapeutic strategies. This study consists of immune, angiogenic, and inflammatory profiling of the tumour microenvironment (TME) and lymph node microenvironment (LNME) in OAC. The prognostic value of nodal involvement and clinicopathological features was compared using a retrospective cohort of OAC patients (n = 702). The expression of inhibitory immune checkpoints by T cells infil

APA, Harvard, Vancouver, ISO, and other styles

21

Tichet, Melanie, Agnieszka Chryplewicz, and Douglas Hanahan. "Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma." Cancer Immunology Research 10, no. 12_Supplement (2022): B41. http://dx.doi.org/10.1158/2326-6074.tumimm22-b41.

Full text

Abstract:

Abstract Cutaneous melanoma is a highly aggressive cancer capable of distant and lethal metastatic spread. Recent breakthroughs have come from understanding oncogenic signaling and cancer immunobiology. Targeted therapies successfully block MAPK signaling in BRAFV600e mutant melanoma with remarkably high clinical responses followed by rapid relapse, whereas checkpoint inhibitors activating the immune response induce long-lasting responses, albeit only in a subset of patients. These limitations have driven interest in understanding innate and acquired resistance. Using an immunocompetent geneti

APA, Harvard, Vancouver, ISO, and other styles

22

Szanto, Celina L., Annelisa M. Cornel, Sara M. Tamminga, et al. "Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma." Cancers 13, no. 9 (2021): 2096. http://dx.doi.org/10.3390/cancers13092096.

Full text

Abstract:

Despite intensive treatment, including consolidation immunotherapy (IT), prognosis of high-risk neuroblastoma (HR-NBL) is poor. Immune status of patients over the course of treatment, and thus immunological features potentially explaining therapy efficacy, are largely unknown. In this study, the dynamics of immune cell subsets and their function were explored in 25 HR-NBL patients at diagnosis, during induction chemotherapy, before high-dose chemotherapy, and during IT. The dynamics of immune cells varied largely between patients. IL-2- and GM-CSF-containing IT cycles resulted in significant e

APA, Harvard, Vancouver, ISO, and other styles

23

Guerriero, Jennifer L. "Abstract IA16: The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy." Cancer Immunology Research 10, no. 12_Supplement (2022): IA16. http://dx.doi.org/10.1158/2326-6074.tumimm22-ia16.

Full text

Abstract:

Abstract Macrophages are an innate immune cell that play a critical role in host defense and maintaining tissue homeostasis, however their infiltration into tumors has been associated with disease progression and resistance to therapy. Tumor associated macrophages (TAMs) represent a significant proportion of solid tumors, including breast cancer. TAMs play a major role in tumorigenesis as they can enhance tumor cell growth, angiogenesis and metastasis. In addition, TAMs can inhibit anti-tumor responses of T cells. Our recent work has shown that removal or conversion of TAMs to an anti-tumor ph

APA, Harvard, Vancouver, ISO, and other styles

24

Dwivedi, Kaushalendra, Anjali Dubey, Jyoti Arya, Mayur Chauhan, Jaya Upreti, and Prashant Katiyar. "A Comprehensive Case Report on the Integrative Ayurveda Approach for Aplastic Anemia." International Journal of Health Sciences and Research 15, no. 2 (2025): 121–26. https://doi.org/10.52403/ijhsr.20250215.

Full text

Abstract:

Aplastic Anemia (AA) is a rare bone marrow failure syndrome caused by the immune system attacking early blood-forming cells. Despite progress in modern medicine, the exact cause and best treatment for AA remain unclear. This case study examines a 38-year-old male with severe Aplastic Anemia who experienced a relapse after initial immuno-suppressive therapy (IST). He was then managed with an integrative approach, incorporating Ayurvedic medicines, specific yogasanas (yogic postures), pranayamas (breathing exercises), and a personalized diet plan. The patient showed remarkable recovery, with sta

APA, Harvard, Vancouver, ISO, and other styles

25

Dominguez Davalos, Marco, José C. De La Flor, Carlos Bedia Castillo, et al. "An Unusual Case of Nephrotic Range Proteinuria in a Short-Standing Type 1 Diabetic Patient with Newly Diagnosed Systemic Lupus Erythematosus: A Case Report and Literature Review." Medical Sciences 12, no. 4 (2024): 74. https://doi.org/10.3390/medsci12040074.

Full text

Abstract:

Background: Lupus podocytopathy (LP) is a non-immune complex-mediated glomerular lesion in systemic lupus erythematosus (SLE), characterized by the diffuse effacement of podocyte processes without immune complex deposition or with only mesangial immune complex deposition. LP is a rare cause of nephrotic syndrome in SLE patients with implications for prognosis and treatment. Case Report: We present the case of a 28-year-old woman with a medical history of type 1 diabetes mellitus (T1DM) who presented with lower limb edema, dyspnea, hypercholesterolemia, with nephrotic range proteinuria, without

APA, Harvard, Vancouver, ISO, and other styles

26

Wodarz, Dominik, and Martin A. Nowak. "Correlates of cytotoxic T–lymphocyte–mediated virus control: implications for immuno–suppressive infections and their treatment." Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 355, no. 1400 (2000): 1059–70. http://dx.doi.org/10.1098/rstb.2000.0643.

Full text

Abstract:

A very important question in immunology is to determine which factors decide whether an immune response can efficiently clear or control a viral infection, and under what circumstances we observe persistent viral replication and pathology. This paper summarizes how mathematical models help us gain new insights into these questions, and explores the relationship between antiviral therapy and long–term immunological control in human immunodeficiency virus (HIV) infection. We find that cytotoxic Tlymphocyte (CTL) memory, defined as antigen–independent persistence of CTL precursors, is necessary f

APA, Harvard, Vancouver, ISO, and other styles

27

Muralinath, E., Kumar Sharma Arun, Padodara D. Ramesh, et al. "Drugs Targeting Hereditary Spherocytosis: A Comprehensive Overview." Journal of Mental health, Psychiatric and Psychosocial Nursing 2, no. 1 (2024): 8–11. https://doi.org/10.5281/zenodo.10669740.

Full text

Abstract:

<em>Hereditary vspherocytosus (HS) is a genetic disorder influencing red blood cells. Resulting </em><em>in </em><em>a</em><em> </em><em>specific spherical shape and an enhanced fragility. One of the essential approaches in managing hereditary spherocytosis is particularly folate supplementation. Folate plays an important role especially in red blood cell production and assists in mitigating the effects of anemia related to HS. By providing an essential component</em><em> of </em><em>DNA synthesis, folate is involved in the formation of healthy red blood cells. In a very cases especially if HS

APA, Harvard, Vancouver, ISO, and other styles

28

Zheng, Xiaobin, Gen Lin, Xinlong Zheng, Feng Long, Kan Jiang, and Tony S. K. Mok. "Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma." Journal of Clinical Oncology 40, no. 16_suppl (2022): e20546-e20546. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e20546.

Full text

Abstract:

e20546 Background: Lung adenosquamous carcinoma (ASC) is an uncommon histological subtype. We aimed to characterize the tumor immune microenvironment (TIME) in lung ASC and estimate patient response to immune checkpoint inhibitors (ICIs), which have never been systematically investigated. Methods: In cohort I, we collected 30 ASCs from a single center for analysis of TIME characteristics, including immuno-phenotyping, tumor mutation burden (TMB), T cell receptor (TCR) repertoires, tumor-infiltrating lymphocytes (TILs), and immune checkpoint expression. In cohort II, the efficacy of ICI-based t

APA, Harvard, Vancouver, ISO, and other styles

29

Kunert, Andre, Anna Oja, Ieva Cesonyte, et al. "Abstract 5234: TGFbeta-conditioned K-NK cells are able to counter immune suppression in the tumor micro-environment." Cancer Research 84, no. 6_Supplement (2024): 5234. http://dx.doi.org/10.1158/1538-7445.am2024-5234.

Full text

Abstract:

Abstract Recent advances have enabled the use of autologous K-NK cells to treat patients suffering from hematological malignancies. When aiming to treat patients suffering from solid tumors however, the suppressive effects of the tumor microenvironment (TME) and the involvement of other immune cells need to be considered to make a cell therapeutic potentially more effective. TGFβ-conditioning (TGFβ-c), the co-culture of K-NK cells with low-dose TGFβ while undergoing cytokine-mediated expansion, imbues these cells with unique qualities suitable to mitigate immuno-suppressive effects of the TME,

APA, Harvard, Vancouver, ISO, and other styles

30

Orlacchio, Arturo, Daniel Weissinger, Catherine Do, Benjamin Tycko, Diane M. Simeone, and Tamas Gonda. "Abstract C041: Hypomethylating therapy induces a potential immuno-suppressive myeloid phenotype by altering cancer cell cytokine secretion in PDAC." Cancer Research 82, no. 22_Supplement (2022): C041. http://dx.doi.org/10.1158/1538-7445.panca22-c041.

Full text

Abstract:

Abstract Introduction: We have previously shown using the KPC (KrasLSL G12D/+; p53 r172H/+; Pdx1-Cre) mouse model of PDAC that sequential treatment with the DNA hypomethylating agents (HMA) followed by anti-PD-1 led to increased tumor necrosis, slowed tumor growth, increased tumor-infiltrating CD8+ cells, and significantly increased mean survival. However, acquired treatment resistance occurred, with emergence of a specific subtype of M2-polarized putatively immunosuppressive Chi3l3+ macrophages. In this study, we characterize the mechanism of polarization of these cells, define their function

APA, Harvard, Vancouver, ISO, and other styles

31

El Hajj, Hiba, Rita Hleihel, Marwan El Sabban, et al. "Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells." Haematologica 106, no. 5 (2021): 1443–56. http://dx.doi.org/10.3324/haematol.2020.264523.

Full text

Abstract:

Adult T cell leukemia/lymphoma (ATL) is associated to chronic human T cell leukemia virus type 1 (HTLV-1) infection and carries a poor prognosis. Arsenic trioxide (AS) and interferon-alpha (IFNα) together selectively trigger Tax viral oncoprotein degradation and cure Tax-driven murine ATL. AS/IFNα/zidovudine treatment achieves a high response rate in patients with chronic ATL. Interleukin 10 (IL-10) is an immuno-suppressive cytokine whose expression is activated by Tax. Here we show that, in ATL, AS/IFNα-induced abrogation of leukemia initiating cell activity requires IL-10 expression shutoff.

APA, Harvard, Vancouver, ISO, and other styles

32

Sayed, Nesrine Ben, Nadia Sassi, Haifa Regaieg, et al. "PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE." HemaSphere 7 (August 2023): e08450f1. http://dx.doi.org/10.1097/01.hs9.0000975076.08450.f1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mercy, K. Sofia, Geetha, and K. M. Kundavi Shankar. "Successful outcome of pregnancy with aplastic anaemia: A case report." Indian Journal of Obstetrics and Gynecology Research 9, no. 1 (2022): 114–17. http://dx.doi.org/10.18231/j.ijogr.2022.022.

Full text

Abstract:

Pregnancy in aplastic anaemia is rare and it may exacerbate bone marrow depression and cause deterioration, which can be life threatening for both mother and child. It poses a great challengeto the haematologist as well as obstetrician as the management of such cases challenges their skills in deciding the best treatment option for the patient. The first report of Aplastic anemia in Pregnancy was publised by Ehrlich in 1888. Haemorrhage and sepsis due to pancytopenia are the mainfactors responsible formortality in pregnant women with aplastic anemia. Treatment options are erythrocytes and plat

APA, Harvard, Vancouver, ISO, and other styles

34

Bourguiba, R., K. Dridi, M. Ayari, et al. "AB1344 DO PATIENTS ON SUPPRESSIVE THERAPY HAVE A DECREASED HUMORAL RESPONSE TO SARS-CoV2 VACCINATION?" Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1903.1–1903. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5599.

Full text

Abstract:

BackgroundSARS-Cov2 vaccination has been shown to be effective against severe forms of SARS-Cov2 infection. Several studies investigated the humoral and cellular response to SARS-Cov2 vaccines in patients followed for autoimmune and inflammatory diseases under immunosuppressive or immunomodulatory treatments. It has been shown that patients on immunosuppressive or immunomodulatory therapies have a poor humoral response to the vaccine[1]ObjectivesThe aim of our study was to investigate the humoral response in patients under conventional immunosuppressive and biotherapies compared to healthy con

APA, Harvard, Vancouver, ISO, and other styles

35

Jose, Aleena, Anuja S Babu, Sampoornna S. Sampoornna S, Sreekutty S. Sreekutty S, Dr J. Nandakumar Dr. J Nandakumar, and Alphonsa Mathew Alphonsa Mathew. "Unmasking the Dangers of Fairness Creams: A Review of Heavy Metal Content and Its Nephrotoxic Effects." International Journal of Pharmaceutical Research and Applications 10, no. 1 (2025): 1299–304. https://doi.org/10.35629/4494-100112991304.

Full text

Abstract:

The skin- whitening creams have been a huge part of society for a fair skin complexion. The benchmark of beauty in many parts of the world today has been entrenched in cultural and historical settings for centuries. These creams may pose serious health risks since many contain heavy metals beyond approved levels.Glomerular diseases, acute renal failure due to ATI and ESKD can be manifestations of kidney damage.When a skin-lightening agent causes heavy metal poisoning in the kidneys, the offending product should be discontinued, management of airway and circulation, chelation therapy and excess

APA, Harvard, Vancouver, ISO, and other styles

36

Kim, Sang-Soo, Joe B. Harford, Manish Moghe, Caroline Doherty, and Esther H. Chang. "A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models." Cells 11, no. 21 (2022): 3434. http://dx.doi.org/10.3390/cells11213434.

Full text

Abstract:

Lung cancer is among the most common and lethal cancers and warrants novel therapeutic approaches to improving patient outcomes. Although immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical benefits, most patients remain unresponsive to currently approved ICIs or develop resistance after initial response. Many ongoing clinical studies are investigating combination therapies to address the limited efficacy of ICIs. Here, we have assessed whether p53 gene therapy via a tumor-targeting nanomedicine (termed SGT-53) can augment anti-programmed cell death-1 (PD-1) immunotherap

APA, Harvard, Vancouver, ISO, and other styles

37

Guerriero, Jennifer L. "Abstract IA011: Modulation of tumor associated macrophages in breast cancer." Cancer Prevention Research 15, no. 12_Supplement_2 (2022): IA011. http://dx.doi.org/10.1158/1940-6215.tacpad22-ia011.

Full text

Abstract:

Abstract Macrophages are an innate immune cell that play a critical role in host defense and maintaining tissue homeostasis, however their infiltration into tumors has been associated with disease progression and resistance to therapy. Tumor associated macrophages (TAMs) represent a significant proportion of solid tumors, including breast cancer. TAMs play a major role in tumorigenesis as they can enhance tumor cell growth, angiogenesis and metastasis. In addition, TAMs can inhibit anti-tumor responses of T cells. Our recent work has shown that removal or conversion of TAMs to an anti-tumor ph

APA, Harvard, Vancouver, ISO, and other styles

38

Caruntu, Ana, Liliana Moraru, Mihaela Surcel, et al. "Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma." Healthcare 10, no. 2 (2022): 342. http://dx.doi.org/10.3390/healthcare10020342.

Full text

Abstract:

Background: Oral squamous cell carcinoma (OSCC) is a common cancer with high morbidity and mortality. Alterations of antitumor immune responses are involved in the development of this malignancy, and investigation of immune changes in the peripheral blood of OSCC patients has aroused the interest of researchers. Methods: In our study, we assessed the proportions of CD3+ total T lymphocytes, CD3+CD4+ helper T lymphocytes, CD3+CD8+ suppressor/cytotoxic T lymphocytes, CD3−CD19+ total B lymphocytes, and CD3−CD16+CD56+ NK cells in the peripheral blood of OSCC patients. Results: The data obtained bo

APA, Harvard, Vancouver, ISO, and other styles

39

Robilliard, Laverne D., Jane Yu, Akshata Anchan, Graeme Finlay, Catherine E. Angel, and E. Scott Graham. "Comprehensive Assessment of Secreted Immuno-Modulatory Cytokines by Serum-Differentiated and Stem-like Glioblastoma Cells Reveals Distinct Differences between Glioblastoma Phenotypes." International Journal of Molecular Sciences 23, no. 22 (2022): 14164. http://dx.doi.org/10.3390/ijms232214164.

Full text

Abstract:

Glioblastoma is refractory to therapy and presents a significant oncological challenge. Promising immunotherapies have not shown the promise observed in other aggressive cancers. The reasons for this include the highly immuno-suppressive tumour microenvironment controlled by the glioblastoma cells and heterogeneous phenotype of the glioblastoma cells. Here, we wanted to better understand which glioblastoma phenotypes produced the regulatory cytokines, particularly those that are implicated in shaping the immune microenvironment. In this study, we employed nanoString analysis of the glioblastom

APA, Harvard, Vancouver, ISO, and other styles

40

Scuoppo, Claudio, Julia Diehl, Ricardo Ramirez, Barry J. Kappel, Abi Vainstein-Haras, and Jim A. Rotolo. "Abstract 3275: Reprogramming of MDSCs by ST316, a clinical peptide antagonist of b-Catenin/BCL9, enhances anti-tumor immuno- and chemotherapy." Cancer Research 85, no. 8_Supplement_1 (2025): 3275. https://doi.org/10.1158/1538-7445.am2025-3275.

Full text

Abstract:

Abstract Myeloid-derived suppressor cells (MDSCs) are a diverse group of immune cells that play critical roles in mediating immune-suppression. They are often associated with poor responses in various cancer types and represent an attractive target for immunotherapy. Challenges in defining the genetic dependencies of MDSCs have hindered the development of effective therapeutic strategies aimed at targeting them. The Wnt/β-catenin signaling pathway is a key oncogenic driver that has been implicated in immune-exclusion, although additional roles in immune-suppression remain unclear. ST316 is a c

APA, Harvard, Vancouver, ISO, and other styles

41

Gkountakos, Anastasios, Pietro Delfino, Rita T. Lawlor, Aldo Scarpa, Vincenzo Corbo, and Emilio Bria. "Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110069. http://dx.doi.org/10.1177/17588359211006947.

Full text

Abstract:

The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint axis, which were initially considered as a late-line treatment option, gradually became the standard of care as first-line treatment for subgroups of NSCLC patients. However, a significant fraction of patients either fails to respond or progresses after a partial response to ICI treatment. Thu

APA, Harvard, Vancouver, ISO, and other styles

42

Hansbro, Philip M., Alison N. Thorburn, Paul S. Foster, and Peter G. Gibson. "Streptococcus pneumoniae vaccine, Prevenar, utilises Tregs to suppress Asthma (140.2)." Journal of Immunology 182, no. 1_Supplement (2009): 140.2. http://dx.doi.org/10.4049/jimmunol.182.supp.140.2.

Full text

Abstract:

Abstract Our recent finding that exposure to Streptococcus pneumoniae may suppress pro-asthmatic responses led us to investigate whether the current human S. pneumoniae vaccines may be used to suppress asthma using mouse models of ovalbumin-(OVA)-induced allergic airways disease (AAD). AAD was induced by intraperitoneal sensitisation and intranasal challenge with OVA. At the time of OVA sensitisation, Prevenar or Pneumovax were delivered intranasally either with or without CpG. Prevenar, but not Pneumovax, suppressed hallmark features of AAD, including eosinophil influx, OVA-specific T helper

APA, Harvard, Vancouver, ISO, and other styles

43

Selvanesan, Benson Chellakkan, Kiran Meena, Amanda Beck, et al. "Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice." Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001250. http://dx.doi.org/10.1136/jitc-2020-001250.

Full text

Abstract:

BackgroundTreatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor’s immune-suppressive stromal compartment. New evidence of positive effects on immune responses in the tumor microenvironment (TME), compelled us to test the combination of gemcitabine (GEM), a standard chemotherapeutic for pancreatic cancer, with nicotinamide (NAM), the amide form of niacin (vitamin B3), in mice with pancreatic cancer.MethodsVarious mouse tumor models of pancreatic cancer, that is, orthotopic Panc-02 and KPC (KrasG12D, p53R172H, Pdx1-Cre) grafts, were treated altern

APA, Harvard, Vancouver, ISO, and other styles

44

Yang, Shao-Ping, Yimin Duan, Xiangliang Yuan, et al. "Abstract C051: Epigenetic reprogramming of brain-infiltrating myeloid cells deters brain metastasis outgrowth." Cancer Research 84, no. 22_Supplement (2024): C051. http://dx.doi.org/10.1158/1538-7445.tumbody-c051.

Full text

Abstract:

Abstract The unique brain immune microenvironment (BrIME) co-evolves with brain metastasis (BrM) and is marked by immune suppression, posing a significant therapeutic challenge. BrIME is dominated by myeloid cells, with monocyte-derived macrophages (MDMs) comprising nearly half of the tumor-infiltrating leukocytes. Targeting MDMs remains challenging due to their inherent heterogeneity and high plasticity, which are regulated by epigenetic modifiers, including histone deacetylases (HDACs). Yet, the impact of HDAC inhibition in BrIME and its implications for BrM immunotherapy remains unclear. He

APA, Harvard, Vancouver, ISO, and other styles

45

MacKinnon, Andrew, Deepthi Bhupathi, Jason Chen, et al. "705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A747. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0705.

Full text

Abstract:

BackgroundTumors evade destruction by the immune system through multiple mechanisms including altering metabolism in the tumor microenvironment. Metabolic control of immune responses occurs through depletion of essential nutrients or accumulation of toxic metabolites that impair immune cell function and promote tumor growth. The secreted enzyme interleukin 4 (IL-4)-induced gene 1 (IL4I1) is an L-phenylalanine oxidase that catabolizes phenylalanine and produces phenyl-pyruvate and hydrogen peroxide. IL4I1 regulates several aspects of adaptive immunity in mice, including inhibition of cytotoxic

APA, Harvard, Vancouver, ISO, and other styles

46

Gu, Shenda, Irene Tang, Shirley Mihardja, et al. "Abstract 4245: QL301, a PD-L1 dependent 4-1BB agonist with enhanced preclinical anti-tumor efficacy and minimal liver toxicity." Cancer Research 82, no. 12_Supplement (2022): 4245. http://dx.doi.org/10.1158/1538-7445.am2022-4245.

Full text

Abstract:

Abstract 4-1BB (CD137, TNFRSF9) is a potent co-stimulatory receptor found on T and NK cells. Activation of 4-1BB requires receptor clustering, which is naturally mediated by the endogenous trimeric 4-1BB ligand. Cross-linking via agnostic monoclonal antibodies can also activate 4-1BB but has generally resulted in unwanted side effects, mainly liver toxicity. To address the shortcomings of 4-1BB agonists, we have developed QL301, a PD-L1 x 4-1BB bispecific antibody that conditionally activates 4-1BB only when concurrently engaged to PD-L1, an immune checkpoint mediator elevated in the immuno-su

APA, Harvard, Vancouver, ISO, and other styles

47

Sharma, Madhav D., Paulo C. Rodriguez, and David H. Munn. "The alarmin cytokine IL-1a drives a feedback-amplification loop between dying tumor cells and inflammatory monocyte-lineage dendritic cells." Journal of Immunology 204, no. 1_Supplement (2020): 170.13. http://dx.doi.org/10.4049/jimmunol.204.supp.170.13.

Full text

Abstract:

Abstract Successful immunotherapy must transform the normally suppressive tumor microenvironment into a pro-inflammatory, immunogenic milieu. We show that this critical transformation depends on a previously unrecognized initiating signal delivered by the damage-associated “alarmin” cytokine interleukin-1a (IL-1a). Initially, tumor-intrinsic IL-1a was mobilized from dying tumor cells. This drove rapid local differentiation of a population of monocyte-lineage inflammatory dendritic cells (DCs). We have previously described these inflammation-inducible myeloid DCs in tumors (Sharma et. al, Immun

APA, Harvard, Vancouver, ISO, and other styles

48

Nguyen, Phuong, Ryan Phennicie, Kevin Kauffman, et al. "862 Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A915. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0862.

Full text

Abstract:

BackgroundMacrophages play an important role in cancer by modulating both the innate and adaptive parts of the immune system. In non-pathological conditions, multiple subsets of macrophages balance the immune response. In cancer, M2-like immune-suppressive tumor-associated macrophages (TAMs) dominate the tumor microenvironment (TME). TAMs promote tumor growth, support neo-angiogenesis and enable metastasis formation. Macrophage modulators driving macrophage repolarization from the M2-like to a pro-inflammatory M1-like phenotype are an attractive novel class of cancer immunotherapy. Here we pre

APA, Harvard, Vancouver, ISO, and other styles

49

Saini, Krishan K., Samanta Sarti, Chelsea L. Rahiman, et al. "Abstract B011: Adenosine signaling and immune modulation in the tumor microenvironment: insights from lung cancer murine model of radiation therapy." Clinical Cancer Research 31, no. 2_Supplement (2025): B011. https://doi.org/10.1158/1557-3265.targetedtherap-b011.

Full text

Abstract:

Abstract Introduction: Radiation therapy (RT) induces adenosine signaling by releasing ATP in the tumor microenvironment (TME), promoting immune suppression and tumor progression. This study investigates how RT impacts adenosine signaling and immune cell infiltration in a preclinical model of non-small cell lung cancer (NSCLC). Using immunophenotyping of tumor-infiltrating immune cells in LLC1 murine model, we aim to explore the potential of targeting the adenosine pathway in combination with RT to enhance antitumor immunity and clinical outcomes. Methods: LLC1 tumor cells (5 x 105) were impla

APA, Harvard, Vancouver, ISO, and other styles

50

Adam, Michael, R. Paul Wilson, Helen Sanderson та ін. "Abstract 2254: Therapeutic depletion of FR-β-positive M2 macrophages in solid tumor indications: A novel IO strategy". Cancer Research 85, № 8_Supplement_1 (2025): 2254. https://doi.org/10.1158/1538-7445.am2025-2254.

Full text

Abstract:

Abstract Traditional IO therapy has primarily focused on T cell checkpoints, however macrophages typically represent the largest immune population present within tumors and can constitute up to 50% of total tumor mass. Macrophages are implicated in both immune mediated control of tumors as well as tumor progression depending on the phenotype of macrophages in the tumor microenvironment (TME). Immune suppressive M2-like tumor associated macrophages (TAMs) release immuno-suppressive cytokines such as IL-10 and TGF-β which promote regulatory T cells, angiogenesis, metastasis, and tumor progressio

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!